Biopharma in India is Surging

According to this article in FierceBiotech a weakened economy and the need for cutbacks is pushing big pharma companies to drive drug development and manufacturing in India. One thing though, many Indian developers are having a hard time transitioning from manufacturing generic drugs to devising new therapies. This is certainly a huge opportunity for Indian firms to thrive if they can ease the transition somehow. It will be interesting to see how things will play out over the course of the next couple of years.

Covance Opens Offices in Ukraine, Slovakia and Israel

Earlier today I came across this post on the Future of Biopharma blog that highlighted an article on ClinicalTrialsToday that details the recent expansion of three new clinical development offices Covance has opened in Central and Eastern Europe and the Middle East.

The purpose of the new offices is to speed clinical trials and develop strategic relationships in those areas. The new offices will be located in Kiev, Ukraine; Bratislava, Slovakia; and Tel Aviv, Israel. Covance has been providing services already in these parts for quite some time, but now these locations will support staff and the CRO’s regional network of field-based clinical research associates.